In 2019, nab-paclitaxel combined with PD-L1 inhibitor was written into the treatment guidelines for metastatic triple negative breast cancer due to its good therapeutic effect with an ORR rate of 56%, much higher than historical ORR of nab-paclitaxel or PD-L1 inhibitor alone (70). This evidence concerns the gene CD274 and triple-negative breast carcinoma.